UCBJF - UCB SA

Other OTC - Other OTC Delayed Price. Currency in USD
85.00
+2.25 (+2.72%)
At close: 9:45AM EST
Stock chart is not supported by your current browser
Previous Close82.75
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. Volume388
Market Cap15.796B
Beta-0.26
PE Ratio (TTM)20.10
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield0.00 (0.00%)
Ex-Dividend Date2016-04-29
1y Target EstN/A
Trade prices are not sourced from all markets
  • UCB SA breached its 50 day moving average in a Bearish Manner : UCBJF-US : November 10, 2017
    Capital Cube2 months ago

    UCB SA breached its 50 day moving average in a Bearish Manner : UCBJF-US : November 10, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for UCB SA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session
    Zacks4 months ago

    Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session

    Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes

  • Parkinson's Now a Hot Therapeutic Area: What's Up Lately?
    Zacks5 months ago

    Parkinson's Now a Hot Therapeutic Area: What's Up Lately?

    Parkinson's disease is a lucrative area due to lack of curative therapy in this space. Many players are trying to bring new treatments to the market. A lot has happened in last couple of months.

  • Capital Cube5 months ago

    UCB SA breached its 50 day moving average in a Bearish Manner : UCBJF-US : August 8, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for UCB SA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • UCB SA :UCBJF-US: Earnings Analysis: For the six months ended June 30, 2017 : August 1, 2017
    Capital Cube6 months ago

    UCB SA :UCBJF-US: Earnings Analysis: For the six months ended June 30, 2017 : August 1, 2017

    Categories: Yahoo FinanceGet free summary analysis UCB SA reports financial results for the half-year ended June 30, 2017. We analyze the earnings along side the following peers of UCB SA – Amgen Inc., Biogen Inc. and Novartis AG Sponsored ADR (AMGN-US, BIIB-US and NVS-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD ... Read more (Read more...)

  • UCB SA breached its 50 day moving average in a Bearish Manner : UCBJF-US : July 25, 2017
    Capital Cube6 months ago

    UCB SA breached its 50 day moving average in a Bearish Manner : UCBJF-US : July 25, 2017

    Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for UCB SA. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bearish 50 ... Read more (Read more...)

  • Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA
    Zacks6 months ago

    Amgen (AMGN) Gets CRL for Osteoporosis Drug Evenity's BLA

    Amgen Inc. (AMGN) and partner UCB SA (UCBJF) announced that the FDA has issued a complete response letter (CRL) for the biologics license application (BLA) for Evenity (romosozumab).

  • Adamas Provides Positive Long-term Data on Parkinson's Drug
    Zacks7 months ago

    Adamas Provides Positive Long-term Data on Parkinson's Drug

    Adamas Pharmaceuticals, Inc. (ADMS) presented expanded analysis from an ongoing open label phase III study EASE LID 2 on its lead candidate, ADS-5102 extended-release capsules.

  • UCB SA :UCBJF-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017
    Capital Cube11 months ago

    UCB SA :UCBJF-US: Earnings Analysis: 2016 By the Numbers : February 28, 2017

    Categories: Yahoo Finance Get free summary analysis UCB SA reports financial results for the year ended December 31, 2016. We analyze the earnings along side the following peers of UCB SA – Shire PLC Sponsored ADR, Amgen Inc., Pfizer Inc., Biogen Inc. and Novartis AG Sponsored ADR (SHPG-US, AMGN-US, PFE-US, BIIB-US and NVS-US) that have also reported for ... Read more (Read more...)